Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Hanover – page 6

648 clinical trials in Hanover, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Hanover at a glance
648
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

648 trials in Hanover

Open in trial search

Age-related macular degeneration

Recruiting

Randomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Factor VIII deficiency

Recruiting

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

Factor VIII deficiency

Recruiting

A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:RO7589655
  • Sponsor:F. Hoffmann-La Roche AG

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Chronic spontaneous urticaria

Recruiting

Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Colorectal cancer metastatic

Recruiting

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

IgA nephropathy

Recruiting

Long-Term Safety Study of Zigakibart in Adults with IgA Nephropathy Who Have Completed Previous Zigakibart Trials

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zigakibart
  • Sponsor:Novartis Pharma AG

Kidney transplant rejection

Recruiting

Frexalimab versus Tacrolimus for Prevention of Kidney Transplant Rejection in Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Immunoglobulin G4 related disease

Recruiting

A study to evaluate the efficacy and safety of rilzabrutinib in adults with active IgG4-related disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Pulmonary arterial hypertension

Recruiting

A study to evaluate the safety and effectiveness of IKT-001 compared to a placebo in adults with pulmonary arterial hypertension.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

Colon cancer

Recruiting

A study to evaluate the safety and effectiveness of darizmetinib hydrochloride in patients who have had liver surgery due to colon cancer metastases

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

Non-small cell lung cancer metastatic

Recruiting

Phase 2 Study of Rinatabart Sesutecan with Pegfilgrastim in Adults with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Hanover

What the registry says about research in the country

01 Respiratory Diseases

Clinical trials focusing on respiratory infections and conditions, including studies of vaccines against RSV and human metapneumovirus in older adults. Research also includes treatment evaluation for chronic obstructive pulmonary disease.

  • RSV vaccine development
  • COPD treatment innovations
  • Viral respiratory infections

Multiple studies are evaluating novel therapeutic approaches for both acute and chronic respiratory conditions.

02 Oncology Research

Innovative trials in cancer treatment, including studies for bladder cancer, multiple myeloma, and advanced breast cancer. Research focuses on combination therapies and novel treatment approaches.

  • Immunotherapy combinations
  • Blood cancer treatments
  • Targeted therapies

Studies emphasize personalized treatment approaches and immune system-based therapies.

03 Neurological Conditions

Research focusing on neurodegenerative diseases, particularly Alzheimer's Disease and Amyotrophic Lateral Sclerosis. Studies evaluate new diagnostic tools and therapeutic interventions.

  • Early-stage dementia treatment
  • ALS therapeutic development
  • Brain clearance mechanisms

Trials aim to address both symptomatic treatment and disease progression.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.